ClinicalTrials.gg
CompletedNCT01217749PCYC-1109-CAUpdated Jun 25, 2015Results posted

Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL

A Phase 1/2 interventional study of PCI-32765 and ofatumumab in B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma and Prolymphocyctic Leukemia, sponsored by Pharmacyclics LLC.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-06-25.

Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
71
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 8 open to participants now, 28 under way, 4 of them phase 3. ibrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
31st of 83
71 · median 44
Started
2010
with 2 others
Phase 1/2
7 of 83
1 open now
Registered
3rd of 83
by date
Lead sponsor
10 of 83
Pharmacyclics LLC.

Among the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 31st largest by enrollment, is one of 3 that started in 2010, is one of 7 in phase 1/2, and was the 3rd registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,038 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

8 of the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy and safety of a fixed-dose, daily regimen of orally administered PCI-32765 combined with ofatumumab in subjects with relapsed/refractory CLL/SLL and related diseases

03

Conditions studied

  • B-cell Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Prolymphocyctic Leukemia
  • Richter's Transformation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects with confirmed chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), prolymphocytic leukemia (PLL), or Richter's transformation arising out of CLL/SLL as defined by WHO classification of hematopoietic neoplasms and satisfying ≥ 1 of the following conditions:

    • Progressive splenomegaly and/or lymphadenopathy identified by physical examination or radiographic studies
    • Anemia (\<11 g/dL) or thrombocytopenia (\<100,000/μL) due to bone marrow involvement
    • Presence of unintentional weight loss > 10% over the preceding 6 months
    • Grade 2 or 3 fatigue
    • Fevers > 100.5 degree or night sweats for > 2 weeks without evidence of infection
    • Progressive lymphocytosis with an increase of > 50% over a 2 month period or an anticipated doubling time of \< 6 months
    • Need for cytoreduction prior to stem cell transplant
  2. Subjects must have failed ≥ 2 prior therapies for CLL including a nucleoside analog or ≥ 2 prior therapies not including nucleoside analog if there is a to such therapy
  3. 10% expression of CD20 on CLL/SLL cells
  4. performance status ≤ 2
  5. ≥ 12 weeks
  6. Subjects must have organ and marrow function as defined below:

    • (ANC) ≥ 1000/µL in the absence of bone marrow involvement
    • ≥ 30,000/μL in the absence of bone marrow involvement
    • Total ≤ 1.5 x institutional unless due to Gilbert's disease
    • (SGOT) ≤ 2.5 x institutional upper limit of normal unless due to infiltration of the liver
    • Creatinine ≤ 2.0 mg/dL OR ≥ 50 mL/min
  7. No history of prior exposure to ofatumumab
  8. Age ≥ 18 years
  9. Body weight ≥ 40 kg

Exclusion criteria

Exclusion Criteria:

  1. A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of PCI-32765 PO, or put the study outcomes at undue risk
  2. Significant cardiovascular disease
  3. Any condition which could interfere with the absorption or metabolism of PCI-32765 including unable to swallow capsules, malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction
  4. Known history of (HIV) or active infection with Virus (HCV) or Virus (HBV) or any uncontrolled active systemic infection
  5. Any anticancer immunotherapy, chemotherapy, radiotherapy, or experimental therapy within 4 weeks before first dose of study drug. for disease-related symptoms are allowed provided 1 week washout occurs
  6. Active central nervous system (CNS) involvement by lymphoma
  7. Major surgery within 4 weeks before first dose of study drug
  8. Lactating or pregnant
  9. Known moderate to severe (COPD)
  10. History of prior , except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for at least 2 years or which will not limit survival to \< 2 years
  11. History of Grade ≥ 2 toxicity continuing from prior anticancer therapy including radiation
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Group 1

    In Group 1, PCI-32765 420 mg PO was administered daily for 1 cycle (28 days) before the start of ofatumumab IV dosing

    Drug: PCI-32765 · Drug: ofatumumab

  • Experimental
    Group 2

    In Group 2, PCI-32765 420 mg PO daily was initiated concomitantly with ofatumumab IV (PCI-32765 initiated on Day 2 of Cycle 1)

    Drug: PCI-32765 · Drug: ofatumumab

  • Experimental
    Group 3

    In Group 3, two cycles of ofatumumab IV were administered prior to the start of PCI-32765 420 mg PO daily

    Drug: PCI-32765 · Drug: ofatumumab

Interventions

  • 420 mg PO daily

    Also known as: ibrutinib

  • per package insert as an IV infusion

    Also known as: Arzerra

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Response

    The primary endpoint for the study was overall response rate (ORR), defined as the proportion of participants who achieved a best overall response of complete response (CR), CR with incomplete blood count recovery (Cri), or partial response (PR), according to the guidelines from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL1) published in 2008 for CLL participants and International Working Group for non-Hodgkin's lymphoma (IWG NHL) 2007 criteria for SLL participants, with the modification that treatment-related lymphocytosis will not be considered progressive disease, as evaluated by the investigators. Assessment of disease is based on radiological exams, physical exam, hematological evaluations and, when appropriate, bone marrow results.

    Time frame: The median follow-up time on study for all treated participants is 12.5 (range 0.5-19.6) months

  2. Safety During Dose-Limiting Toxicity (DLT) Observation Period

    Number of dose-limiting toxicities observed in the first 6 participants enrolled in treatment Groups 1 and 2

    Time frame: 56 days for Group 1 and 28 days for Group 2

Secondary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (AEs)

    Number of participants who had experienced at least one treatment emergent AE

    Time frame: From first dose of study treatment to within 30 days of last dose or until study closure

  2. Progression Free Survival (PFS) at 12 Months

    Progressive disease for CLL (Hallek) is characterized by ≥1 of the following: * Appearance of any new lesion, eg lymph nodes (\> 1.5 cm), de novo hepatomegaly or splenomegaly, or other organ infiltrates * Increase of ≥50% * in longest diameter of any previous site * in hepatomegaly or splenomegaly * in blood lymphocytes with ≥5x109/L B cells with enlarging lymph node, liver, or spleen Progressive disease for B cell lymphoma (Cheson) is characterized by any new lesion or increase by ≥ 50% of previously involved sites from nadir: * Appearance of a new lesion(s) \>1.5 cm in any axis, ≥ 50% increase in the SPD of \>1 node, or ≥50% increase in longest diameter of a previously identified node \>1 cm in short axis * Lesions PET+ if FDG-avid lymphoma or PET+ before therapy * 50% increase from nadir in the SPD of any liver or spleen lesions * New or recurrent BM involvement * Increase of ≥50% in blood lymphocytes with ≥5x109/L B cells within enlarging lymph node, liver, or spleen

    Time frame: From first dose of study treatment until disease progression, death, or until 12 months

07

Results

Posted Apr 16, 2015

Participant flow

Participant flow — Overall Study
MilestoneGroup 1Group 2Group 3
Started272024
Completed241722
Not completed332

Outcome measures

PrimaryPercentage of Participants Achieving Response

The primary endpoint for the study was overall response rate (ORR), defined as the proportion of participants who achieved a best overall response of complete response (CR), CR with incomplete blood count recovery (Cri), or partial response (PR), according to the guidelines from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL1) published in 2008 for CLL participants and International Working Group for non-Hodgkin's lymphoma (IWG NHL) 2007 criteria for SLL participants, with the modification that treatment-related lymphocytosis will not be considered progressive disease, as evaluated by the investigators. Assessment of disease is based on radiological exams, physical exam, hematological evaluations and, when appropriate, bone marrow results.

Time frame:
The median follow-up time on study for all treated participants is 12.5 (range 0.5-19.6) months
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Response
percentage of participantsGroup 1Group 2Group 3
Percentage of Participants Achieving Response92.6 (75.7 to 99.1)80.0 (56.3 to 94.3)70.8 (48.9 to 87.4)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (AEs)

Number of participants who had experienced at least one treatment emergent AE

Time frame:
From first dose of study treatment to within 30 days of last dose or until study closure
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (AEs)
participantsGroup 1Group 2Group 3
Number of Participants With Treatment Emergent Adverse Events (AEs)272024
SecondaryProgression Free Survival (PFS) at 12 Months

Progressive disease for CLL (Hallek) is characterized by ≥1 of the following: * Appearance of any new lesion, eg lymph nodes (\> 1.5 cm), de novo hepatomegaly or splenomegaly, or other organ infiltrates * Increase of ≥50% * in longest diameter of any previous site * in hepatomegaly or splenomegaly * in blood lymphocytes with ≥5x109/L B cells with enlarging lymph node, liver, or spleen Progressive disease for B cell lymphoma (Cheson) is characterized by any new lesion or increase by ≥ 50% of previously involved sites from nadir: * Appearance of a new lesion(s) \>1.5 cm in any axis, ≥ 50% increase in the SPD of \>1 node, or ≥50% increase in longest diameter of a previously identified node \>1 cm in short axis * Lesions PET+ if FDG-avid lymphoma or PET+ before therapy * 50% increase from nadir in the SPD of any liver or spleen lesions * New or recurrent BM involvement * Increase of ≥50% in blood lymphocytes with ≥5x109/L B cells within enlarging lymph node, liver, or spleen

Time frame:
From first dose of study treatment until disease progression, death, or until 12 months
Reported as:
Mean · percentage of event free participants
Progression Free Survival (PFS) at 12 Months
percentage of event free participantsGroup 1Group 2Group 3
Progression Free Survival (PFS) at 12 Months88.7 (69.0 to 96.2)85.0 (60.4 to 94.9)75.0 (52.6 to 87.9)
PrimarySafety During Dose-Limiting Toxicity (DLT) Observation Period

Number of dose-limiting toxicities observed in the first 6 participants enrolled in treatment Groups 1 and 2

Time frame:
56 days for Group 1 and 28 days for Group 2
Reported as:
Number · participants who experienced DLT
Safety During Dose-Limiting Toxicity (DLT) Observation Period
participants who experienced DLTGroup 1Group 2
Safety During Dose-Limiting Toxicity (DLT) Observation Period00

Adverse events

Collected over From first dose of study treatment to within 30 days of last dose or until study closure. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1—12/27 (44.4%)27/27 (100%)
Group 2—9/20 (45%)20/20 (100%)
Group 3—10/24 (41.7%)24/24 (100%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventGroup 1Group 2Group 3
PneumoniaInfections and infestations4/273/204/24
CellulitisInfections and infestations1/270/202/24
DyspnoeaRespiratory, thoracic and mediastinal disorders0/271/202/24
Atrial fibrillationCardiac disorders2/271/201/24
Myocardial infarctionCardiac disorders2/270/200/24
DehydrationMetabolism and nutrition disorders2/270/200/24
Febrile neutropeniaBlood and lymphatic system disorders0/271/201/24
PyrexiaGeneral disorders0/271/200/24
Viral upper respiratory tract infectionInfections and infestations0/271/200/24
Subdural haematomaInjury, poisoning and procedural complications0/271/200/24
Most frequent other events
Showing 10 of 249
Most frequent other events
EventGroup 1Group 2Group 3
DiarrhoeaGastrointestinal disorders18/2716/2016/24
Infusion related reactionInjury, poisoning and procedural complications9/2714/209/24
Peripheral sensory neuropathyNervous system disorders11/278/2012/24
FatigueGeneral disorders13/271/201/24
StomatitisGastrointestinal disorders11/279/207/24
Upper respiratory tract infectionInfections and infestations7/278/205/24
ContusionInjury, poisoning and procedural complications9/278/203/24
Increased tendency to bruiseBlood and lymphatic system disorders10/275/202/24
Muscle spasmsMusculoskeletal and connective tissue disorders10/274/202/24
NauseaGastrointestinal disorders5/276/206/24

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Group 1Group 2Group 3Total
<=18 years0000
Between 18 and 65 years13121540
>=65 years148931
Sex: Female, Male
Sex: Female, Male(Participants)Group 1Group 2Group 3Total
Female87722
Male19131749
Region of Enrollment
Region of Enrollment(participants)Group 1Group 2Group 3Total
United States27202471
08

Study locations

1 site
  • The Ohio State University
    Columbus, Ohio 43210, United States
09

References and documents

Publications

  • Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, Lacey SF, Melenhorst JJ, McGettigan SE, Cook DR, Zhang C, Xu J, Do P, Hulitt J, Kudchodkar SB, Cogdill AP, Gill S, Porter DL, Woyach JA, Long M, Johnson AJ, Maddocks K, Muthusamy N, Levine BL, June CH, Byrd JC, Maus MV. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016 Mar 3;127(9):1117-27. doi: 10.1182/blood-2015-11-679134. Epub 2016 Jan 26. PubMed 26813675 ↗
  • Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncol. 2015 Apr;1(1):80-7. doi: 10.1001/jamaoncol.2014.218. PubMed 26182309 ↗
  • Jaglowski SM, Jones JA, Nagar V, Flynn JM, Andritsos LA, Maddocks KJ, Woyach JA, Blum KA, Grever MR, Smucker K, Ruppert AS, Heerema NA, Lozanski G, Stefanos M, Munneke B, West JS, Neuenburg JK, James DF, Hall N, Johnson AJ, Byrd JC. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood. 2015 Aug 13;126(7):842-50. doi: 10.1182/blood-2014-12-617522. Epub 2015 Jun 26. PubMed 26116658 ↗
  • Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, Stefanovski MR, Chappell DL, Frissora FW, Smith LL, Smucker KA, Flynn JM, Jones JA, Andritsos LA, Maddocks K, Lehman AM, Furman R, Sharman J, Mishra A, Caligiuri MA, Satoskar AR, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JC. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013 Oct 10;122(15):2539-49. doi: 10.1182/blood-2013-06-507947. Epub 2013 Jul 25. PubMed 23886836 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Jun 2013 and a completion of May 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2015, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2010
First posted
Oct 8, 2010
Start
Dec 2010
Primary completionActual
Jun 2013
CompletionActual
May 2014
Results first posted
Apr 16, 2015
Last update
Jun 25, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01217749
Lead sponsor
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Oct 8, 2010
Start date
Dec 2010
Primary completion
Jun 2013
Completion
May 2014
Results posted
Apr 16, 2015
Last update
Jun 25, 2015

Study contacts

Samantha Jaglowski, MD
principal investigator · Ohio State University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion